Why Tesaro went NOVA

Why 'best case scenario' boosts Tesaro on PARP data

Even though one marketed PARP inhibitor already has demonstrated that its mechanism works as maintenance therapy in platinum-sensitive ovarian cancer, Tesaro Inc. (NASDAQ:TSRO) soared on its positive Phase III data for niraparib (MK-4827) because it was "a best case scenario," according to one investor.

On June 29, Tesaro climbed $40.19 (108%) to $77.40

Read the full 547 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers